Login to Your Account



JPM 2015

Immune Design laying the groundwork for future PD-1 combo

By Michael Fitzhugh
Staff Writer

Thursday, January 15, 2015

Immune Design Corp. CEO Carlos Paya told attendees at the J.P. Morgan Healthcare Conference Thursday the company is making solid progress toward what he believes is the future of in vivo cancer immunotherapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription